BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nabhan C, Smith SM, Kahl BS. Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies. Leuk Lymphoma 2012;53:770-8. [PMID: 21958083 DOI: 10.3109/10428194.2011.628061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Roschewski M, Hill BT. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma? Am Soc Clin Oncol Educ Book 2019;39:467-76. [PMID: 31099693 DOI: 10.1200/EDBK_239065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Shah BD, Martin P, Sotomayor EM. Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer Control 2012;19:227-35. [PMID: 22710898 DOI: 10.1177/107327481201900307] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
3 Olszewski AJ, Shafqat H, Ali S. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. Leuk Lymphoma 2015;56:942-50. [PMID: 24956144 DOI: 10.3109/10428194.2014.936013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
4 Nabhan C, Ollberding NJ, Villines D, Chiu BC, Caces DB, Valdez TV, Ghielmini M, Hsu Schmitz SF, Smith SM. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leuk Lymphoma 2014;55:1288-94. [PMID: 23998254 DOI: 10.3109/10428194.2013.839787] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
5 Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, Dundar Y, Hockenhull J, Proudlove C, Chu P. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal. Pharmacoeconomics 2013;31:403-13. [PMID: 23576017 DOI: 10.1007/s40273-013-0043-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]